| review article | Q7318358 |
| scholarly article | Q13442814 |
| P2093 | author name string | Vikas Gupta | |
| Rebecca Devlin | |||
| P2860 | cites work | Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2 | Q24568313 |
| Hematopoietic Cell Transplantation as Curative Therapy for Patients with Myelofibrosis: Long-Term Success in all Age Groups | Q26786893 | ||
| CALR and ASXL1 mutations-based molecular prognostication in primary myelofibrosis: an international study of 570 patients | Q27852820 | ||
| Correlation of mutation profile and response in patients with myelofibrosis treated with ruxolitinib | Q27853179 | ||
| CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons | Q29998841 | ||
| Splenectomy in myelofibrosis with myeloid metaplasia: a single-institution experience with 223 patients. | Q33331903 | ||
| Refined cytogenetic-risk categorization for overall and leukemia-free survival in primary myelofibrosis: a single center study of 433 patients | Q33392291 | ||
| Allogeneic haematopoietic stem cell transplantation for myelofibrosis: a report of the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC). | Q33393151 | ||
| DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status | Q33393245 | ||
| JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis | Q33399977 | ||
| Splenectomy and hemopoietic stem cell transplantation for myelofibrosis | Q73709920 | ||
| Hematopoietic cell transplantation as curative therapy for idiopathic myelofibrosis, advanced polycythemia vera, and essential thrombocythemia | Q79817900 | ||
| Different outcome of allogeneic transplantation in myelofibrosis using conventional or reduced-intensity conditioning regimens | Q80262366 | ||
| A retrospective comparison of conventional intensity conditioning and reduced-intensity conditioning for allogeneic hematopoietic cell transplantation in myelofibrosis | Q83388958 | ||
| The outcome of allo-HSCT for 92 patients with myelofibrosis in the Nordic countries | Q84065231 | ||
| Splenectomy after allogeneic haematopoietic stem cell transplantation in patients with primary myelofibrosis | Q84552610 | ||
| SRSF2 mutations in primary myelofibrosis: significant clustering with IDH mutations and independent association with inferior overall and leukemia-free survival | Q84962229 | ||
| Activity of therapeutic JAK 1/2 blockade in graft-versus-host disease | Q87635679 | ||
| A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis | Q33399980 | ||
| Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis | Q33411211 | ||
| Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis | Q33416223 | ||
| Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I. | Q33419957 | ||
| Allogeneic transplantation for primary myelofibrosis with BM, peripheral blood or umbilical cord blood: an analysis of the JSHCT | Q33556843 | ||
| Allogeneic hematopoietic stem cell transplantation in patients with polycythemia vera or essential thrombocythemia transformed to myelofibrosis or acute myeloid leukemia: a report from the MPN Subcommittee of the Chronic Malignancies Working Party o | Q33558748 | ||
| Measurement and impact of comorbidity in older cancer patients | Q34014917 | ||
| Outcome of transplantation for myelofibrosis | Q34015474 | ||
| Somatic mutations of calreticulin in myeloproliferative neoplasms | Q34039270 | ||
| MPD-RC 101 prospective study of reduced-intensity allogeneic hematopoietic stem cell transplantation in patients with myelofibrosis | Q34047897 | ||
| Impact of allogeneic stem cell transplantation on survival of patients less than 65 years of age with primary myelofibrosis. | Q35634902 | ||
| The Dynamic International Prognostic Scoring System for myelofibrosis predicts outcomes after hematopoietic cell transplantation | Q35849342 | ||
| Allogeneic hematopoietic stem cell transplantation for myelofibrosis | Q36385798 | ||
| A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis | Q36708975 | ||
| Effects of spleen status on early outcomes after hematopoietic cell transplantation | Q36712192 | ||
| Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Myelofibrosis with Prior Exposure to Janus Kinase 1/2 Inhibitors. | Q37272164 | ||
| Reduced-intensity hematopoietic cell transplantation for patients with primary myelofibrosis: a cohort analysis from the center for international blood and marrow transplant research. | Q37457111 | ||
| Allogeneic hematopoietic cell transplantation for myelofibrosis in the era of JAK inhibitors | Q38018908 | ||
| Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis: A Randomized Clinical Trial | Q38407900 | ||
| Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: a consensus process by an EBMT/ELN international working group | Q38570614 | ||
| Incidence and risk factors of poor graft function after allogeneic stem cell transplantation for myelofibrosis | Q38879870 | ||
| The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo-controlled, Phase III study in patients with myelofibrosis | Q40625383 | ||
| Pharmacologic Inhibition of JAK1/JAK2 Signaling Reduces Experimental Murine Acute GVHD While Preserving GVT Effects | Q40936847 | ||
| Changes in quality of life and disease-related symptoms in patients with polycythemia vera receiving ruxolitinib or standard therapy | Q41095829 | ||
| JAK inhibition induces silencing of T Helper cytokine secretion and a profound reduction in T regulatory cells | Q41160178 | ||
| Improved Outcome of Alternative Donor Transplantations in Patients with Myelofibrosis: From Unrelated to Haploidentical Family Donors. | Q41235146 | ||
| Effect of conditioning regimens on graft failure in myelofibrosis: a retrospective analysis | Q41519713 | ||
| Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation | Q43265365 | ||
| Allogeneic hematopoietic stem cell transplantation in myelofibrosis: the 20-year experience of the Gruppo Italiano Trapianto di Midollo Osseo (GITMO). | Q44707716 | ||
| Treatment outcomes following leukemic transformation in Philadelphia-negative myeloproliferative neoplasms. | Q45905329 | ||
| Allogeneic hemopoietic SCT for patients with primary myelofibrosis: a predictive transplant score based on transfusion requirement, spleen size and donor type | Q47174502 | ||
| Allogeneic hematopoietic cell transplantation for myelofibrosis in patients pretreated with the JAK1 and JAK2 inhibitor ruxolitinib. | Q53099028 | ||
| Leukemia risk models in primary myelofibrosis: an International Working Group study. | Q53136481 | ||
| Risk models predicting survival after reduced-intensity transplantation for myelofibrosis. | Q53136705 | ||
| Outcome after Transplantation According to Reduced-Intensity Conditioning Regimen in Patients Undergoing Transplantation for Myelofibrosis. | Q53198934 | ||
| Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms. | Q54225327 | ||
| Development of extramedullary sites of leukaemia during ruxolitinib therapy for myelofibrosis. | Q54349909 | ||
| Type 1 vs type 2 calreticulin mutations in primary myelofibrosis: differences in phenotype and prognostic impact. | Q54374932 | ||
| JAK inhibition with ruxolitinib as pretreatment for allogeneic stem cell transplantation in primary or post-ET/PV myelofibrosis. | Q54374933 | ||
| EZH2 mutational status predicts poor survival in myelofibrosis. | Q54560112 | ||
| The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patients | Q58455624 | ||
| Allogeneic hematopoietic cell transplantation for myelofibrosis using fludarabine-, intravenous busulfan- and low-dose TBI-based conditioning | Q60710884 | ||
| Incidence and Risk Factors for Early Hepatotoxicity and Its Impact on Survival in Patients with Myelofibrosis Undergoing Allogeneic Hematopoietic Cell Transplantation | Q60710980 | ||
| P433 | issue | 1 | |
| P921 | main subject | myelofibrosis | Q1752571 |
| P304 | page(s) | 543-551 | |
| P577 | publication date | 2016-12-01 | |
| P1433 | published in | Hematology / the Education Program of the American Society of Hematology | Q26842068 |
| P1476 | title | Myelofibrosis: to transplant or not to transplant? | |
| P478 | volume | 2016 |
| Q91893832 | Determinants of survival in myelofibrosis patients undergoing allogeneic hematopoietic cell transplantation |
| Q89777328 | Impact of genomic alterations on outcomes in myelofibrosis patients undergoing JAK1/2 inhibitor therapy |
| Q90547544 | Management of myelofibrosis after ruxolitinib failure |
| Q39027848 | Mutations in MPNs: prognostic implications, window to biology, and impact on treatment decisions |
| Q90064075 | Patterns of Ruxolitinib Therapy Failure and Its Management in Myelofibrosis: Perspectives of the Canadian Myeloproliferative Neoplasm Group |
Search more.